New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 13, 2012
10:24 EDTAMT, ABC, CELG, ITW, NOK, PPL, JBHTOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Tower (AMT) downgraded to Neutral from Overweight at Piper Jaffray... AmerisourceBergen (ABC) downgraded to Equal Weight from Overweight at Morgan Stanley... Celgene (CELG) downgraded to Hold from Buy at Auriga... Illinois Tool Works (ITW) downgraded to Underweight from Equal Weight at Morgan Stanley... Nokia (NOK) downgraded to Equal Weight from Overweight at Barclays... PPL Corp. (PPL) downgraded to Buy from Conviction Buy at Goldman... J.B. Hunt (JBHT) downgraded to Neutral from Buy at Sterne Agee.
News For AMT;ABC;CELG;ITW;NOK;PPL;JBHT From The Last 14 Days
Check below for free stories on AMT;ABC;CELG;ITW;NOK;PPL;JBHT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
05:52 EDTNOKStocks with implied volatility movement; NOK WLT
Stocks with implied volatility movement; Nokia (NOK) 30, Walter Energy (WLT) 62 according to iVolatility.
August 20, 2014
08:02 EDTCELGBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
August 19, 2014
09:38 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD
07:33 EDTCELGCelgene announces publication of REVLIMID combination results
Celgene announced that results of a study evaluating the combination of REVLIMID with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone in untreated diffuse large b-cell lymphoma were published online ahead of print in the Journal of Clinical Oncology. In a phase II, open label, single arm study, 64 patients with newly diagnosed, untreated, stage II-IV CD20 positive DLBCL received 25 mg of lenalidomide on days 1-10 with standard dose R-CHOP every 21 days for six cycles. All patients received pegfilgrastim on day two of each cycle and aspirin prophylaxis throughout. The primary endpoint was event-free survival with secondary endpoints of progression free survival and overall survival. A one-stage binomial design was used to assess the efficacy and tolerability of REVLIMID with R-CHOP. Of the 64 patients enrolled, 60 were eligible for response evaluation. In these patients, the overall response rate was 98% with 80% achieving a complete response. The 24-month EFS, which was identical to PFS, and OS rates were 59% and 78%, respectively. The company said, "This study demonstrated that the addition of lenalidomide to conventional R-CHOP resulted in similar PFS rates and OS rates between sub-types. This is intriguing as patients with the non-GCB phenotype have traditionally experienced poorer outcomes. The results of this study support further evaluation of this regimen in this sub-type of DLBCL.
August 18, 2014
08:47 EDTAMTRaymond James to hold a summit
Subscribe for More Information
August 14, 2014
18:04 EDTNOKInterDigital loses patent case against Nokia, ZTE, Bloomberg reports
Subscribe for More Information
17:00 EDTNOKGreenlight Capital gives quarterly update on stakes
Subscribe for More Information
13:56 EDTNOKVodafone selects Nokia Networks to launch LTE network in New Zealand
Subscribe for More Information
09:07 EDTAMTMorgan Stanley to hold a conference
Subscribe for More Information
August 12, 2014
10:23 EDTITWIllinois Tool Works repeats view of FY14 EPS $4.50-$4.62, consensus $4.59
Subscribe for More Information
10:21 EDTITWIllinois Tool Works repeats view of Q3 EPS $1.19-$1.27, consensus $1.24
Subscribe for More Information
August 8, 2014
13:08 EDTITWIllinois Tool Works board increases quarterly dividend by 15% to 48.5c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use